4//SEC Filing
Versant Venture Capital VI, L.P. 4
Accession 0001193125-25-213445
CIK 0001840748other
Filed
Sep 22, 8:00 PM ET
Accepted
Sep 23, 4:33 PM ET
Size
16.8 KB
Accession
0001193125-25-213445
Insider Transaction Report
Form 4
Versant Venture Capital VI, L.P.
10% Owner
Transactions
- Sale
Common Stock
2025-09-19$1.40/sh−2,370,533$3,322,065→ 0 total - Sale
Common Stock
2025-09-19$1.40/sh−532,870$746,764→ 0 total(indirect: See Footnote)
Versant Ventures VI GP, L.P.
10% Owner
Transactions
- Sale
Common Stock
2025-09-19$1.40/sh−532,870$746,764→ 0 total(indirect: See Footnote) - Sale
Common Stock
2025-09-19$1.40/sh−2,370,533$3,322,065→ 0 total
Versant Ventures VI GP-GP, LLC
10% Owner
Transactions
- Sale
Common Stock
2025-09-19$1.40/sh−532,870$746,764→ 0 total(indirect: See Footnote) - Sale
Common Stock
2025-09-19$1.40/sh−2,370,533$3,322,065→ 0 total
Versant Vantage I, L.P.
10% Owner
Transactions
- Sale
Common Stock
2025-09-19$1.40/sh−532,870$746,764→ 0 total(indirect: See Footnote) - Sale
Common Stock
2025-09-19$1.40/sh−2,370,533$3,322,065→ 0 total
Versant Vantage I GP, L.P.
10% Owner
Transactions
- Sale
Common Stock
2025-09-19$1.40/sh−2,370,533$3,322,065→ 0 total - Sale
Common Stock
2025-09-19$1.40/sh−532,870$746,764→ 0 total(indirect: See Footnote)
Versant Vantage I GP-GP, LLC
10% Owner
Transactions
- Sale
Common Stock
2025-09-19$1.40/sh−2,370,533$3,322,065→ 0 total - Sale
Common Stock
2025-09-19$1.40/sh−532,870$746,764→ 0 total(indirect: See Footnote)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.40 to $1.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- [F2]These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
- [F3]These shares are held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Each of VV I GP-GP and VV I GP may be deemed to share voting, investment and dispositive power over the shares held by VV I and disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
Documents
Issuer
LAVA Therapeutics NV
CIK 0001840748
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001687880
Filing Metadata
- Form type
- 4
- Filed
- Sep 22, 8:00 PM ET
- Accepted
- Sep 23, 4:33 PM ET
- Size
- 16.8 KB